Success is hard to come by in drug development. “On average, 50% of phase III trials with novel therapeutics fail,” says Subha Madhavan, vice president and head of AI/ML at Pfizer. “A primary reason ...
Hosted on MSN
Master the art of reading medical research
Why bias matters: Bias can creep into any stage of research, distorting results and leading to flawed conclusions that may harm patient care. Stats vs. real life: A statistically significant result ...
- Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study - Japan Phase 3 results strengthen CARTISTEM's® global commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results